昊海生物科技(06826)发布2025年度业绩，股东应占利润2.51亿元，同比下降40.3%

智通财经

Mar 20

智通财经APP讯，昊海生物科技(06826)发布截至2025年12月31日止年度业绩，收入24.46亿元(人民币，下同)，同比下降8.7%;母公司拥有人应占利润2.51亿元，同比下降40.3%;每股基本盈利1.08元，拟派末期股息为每股0.60元(含税)。

报告期内，集团经营业绩面临多重外部因素叠加影响。一方面，主要子公司上海其胜受增值税税率从3%调增至13%的影响，导致报告期内相关产品的扣税后销售单价及销售收入均有所下降。另一方面，人工晶状体产品国家带量采购进入两年协议期的第二阶段，叠加行业竞争格局日趋激烈，市场竞品数量增加，尤其是国产人工晶状体产品凭借显著的成本和价格优势，对进口品牌产品形成更大的挑战;加上2025年国内白内障手术总量较2024年有所下降，市场整体需求回落，集团人工晶状体业务的经营业绩不及预期。此外，结合2026年上半年将启动人工晶状体产品第二轮国家集中带量采购的产品降价预期，基于审慎性原则，集团对下属从事美国进口Lenstec品牌人工晶状体业务的子公司深圳新产业商誉计提减值准备约人民币1.41亿元，并对下属从事Aaren品牌人工晶状体产品生产和销售的美国子公司Aaren Scientific Inc.所持有的无形资产——品牌计提减值准备约人民币2500万元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2620673217"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620673217\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620673217?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-20 22:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620673217","market":"us","top_or_hot":-1,"title":"昊海生物科技(06826)发布2025年度业绩，股东应占利润2.51亿元，同比下降40.3%","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/06826\">昊海生物科技</a>(06826)发布截至2025年12月31日止年度业绩，收入24.46亿元(人民币，下同)，同比下降8.7%;母公司拥有人应占利润2.51亿元，同比下降40.3%;每股基本盈利1.08元，拟派末期股息为每股0.60元(含税)。</p><p>报告期内，集团经营业绩面临多重外部因素叠加影响。一方面，主要子公司上海其胜受增值税税率从3%调增至13%的影响，导致报告期内相关产品的扣税后销售单价及销售收入均有所下降。另一方面，人工晶状体产品国家带量采购进入两年协议期的第二阶段，叠加行业竞争格局日趋激烈，市场竞品数量增加，尤其是国产人工晶状体产品凭借显著的成本和价格优势，对进口品牌产品形成更大的挑战;加上2025年国内白内障手术总量较2024年有所下降，市场整体需求回落，集团人工晶状体业务的经营业绩不及预期。此外，结合2026年上半年将启动人工晶状体产品第二轮国家集中带量采购的产品降价预期，基于审慎性原则，集团对下属从事美国进口Lenstec品牌人工晶状体业务的子公司深圳<a href=\"https://laohu8.com/S/300832\">新产业</a>商誉计提减值准备约人民币1.41亿元，并对下属从事Aaren品牌人工晶状体产品生产和销售的美国子公司Aaren Scientific Inc.所持有的无形资产——品牌计提减值准备约人民币2500万元。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>昊海生物科技(06826)发布2025年度业绩，股东应占利润2.51亿元，同比下降40.3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n昊海生物科技(06826)发布2025年度业绩，股东应占利润2.51亿元，同比下降40.3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-20 22:35 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1416953.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，昊海生物科技(06826)发布截至2025年12月31日止年度业绩，收入24.46亿元(人民币，下同)，同比下降8.7%;母公司拥有人应占利润2.51亿元，同比下降40.3%;每股基本盈利1.08元，拟派末期股息为每股0.60元(含税)。报告期内，集团经营业绩面临多重外部因素叠加影响。一方面，主要子公司上海其胜受增值税税率从3%调增至13%的影响，导致报告期内相关产品的扣税后销售...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1416953.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1416953.html","article_id":"2620673217","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620673217","pubTimestamp":1774017322,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，昊海生物科技 发布截至2025年12月31日止年度业绩，收入24.46亿元，同比下降8.7%;母公司拥有人应占利润2.51亿元，同比下降40.3%;每股基本盈利1.08元，拟派末期股息为每股0.60元(含税)。报告期内，集团经营业绩面临多重外部因素叠加影响。一方面，主要子公司上海其胜受增值税税率从3%调增至13%的影响，导致报告期内相关产品的扣税后销售单价及销售收入均有所下降。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","BK1593":"医美概念股","06826":"昊海生物科技"},"translate_title":"Haohai Biotechnology (06826) released its 2025 annual results, with a profit attributable to shareholders of 251 million yuan, down 40.3% year-on-year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06826":1.5},"content_text":"智通财经APP讯，昊海生物科技(06826)发布截至2025年12月31日止年度业绩，收入24.46亿元(人民币，下同)，同比下降8.7%;母公司拥有人应占利润2.51亿元，同比下降40.3%;每股基本盈利1.08元，拟派末期股息为每股0.60元(含税)。报告期内，集团经营业绩面临多重外部因素叠加影响。一方面，主要子公司上海其胜受增值税税率从3%调增至13%的影响，导致报告期内相关产品的扣税后销售单价及销售收入均有所下降。另一方面，人工晶状体产品国家带量采购进入两年协议期的第二阶段，叠加行业竞争格局日趋激烈，市场竞品数量增加，尤其是国产人工晶状体产品凭借显著的成本和价格优势，对进口品牌产品形成更大的挑战;加上2025年国内白内障手术总量较2024年有所下降，市场整体需求回落，集团人工晶状体业务的经营业绩不及预期。此外，结合2026年上半年将启动人工晶状体产品第二轮国家集中带量采购的产品降价预期，基于审慎性原则，集团对下属从事美国进口Lenstec品牌人工晶状体业务的子公司深圳新产业商誉计提减值准备约人民币1.41亿元，并对下属从事Aaren品牌人工晶状体产品生产和销售的美国子公司Aaren Scientific Inc.所持有的无形资产——品牌计提减值准备约人民币2500万元。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}